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Background: CD40-CD40 ligand (CD40L) interaction is considered to contribute to the promotion of prothrombotic
responses and production of angiogenesis-associated factor in addition to adaptive immune responses. Recently, the
role of soluble CD40L (sCD40L) has gained interest in cancer, although its exact functions remain unknown. This study
evaluated the clinical significance of sCD40L in patients with pancreatic ductal adenocarcinoma (PDAC) and validated
its utility as a PDAC diagnostic and prognostic biomarker.
Methods: Serum sCD40L levels were measured by chemiluminescent immunoassay and compared among normal,
chronic pancreatitis (CP, high-risk), and PDAC group in both training (n = 25 per group) and independent validation
(n = 30, 30, and 55, respectively) datasets through one-way ANOVA test with the post-hoc Bonferroni method. To
evaluate the diagnostic potential of serum sCD40L for PDAC, receiver operating characteristic (ROC) curves were
generated and logistic regression analysis was conducted. To investigate the sCD40L-assoicated cytokines/chemokines
in PDAC, cytokines/chemokines levels were analyzed by a MILLIPLEX MAP Human Cytokine/Chemokine Kit. To assess
the prognostic potentials of sCD40L, Kaplan-Meier survival curve and Cox proportional-hazards regression analysis
were applied.
Results: Serum sCD40L levels were significantly higher in PDAC group compared with non-cancer groups in both
training (p < 0.05) and validation (p < 0.05) datasets. Clinically, serum sCD40L closely correlated with unresectability
(γs = 0.342, p = 0.011) and distant metastasis (γs = 0.294, p = 0.030) of PDAC. ROC curve and logistic regression analysis
demonstrated the remarkable predictive potentials of serum sCD40L for PDAC (80.0% sensitivity and 85.5% specificity
at cut-off point, 0.45; logistic regression), superior to those of CA19-9 and CEA. According to cytokines/chemokines
assay, serum sCD40L levels were closely correlated with serum levels of pro-angiogenic cytokines (EGF, VEGF, IL-8)
and immunosuppressive cytokines (IL-6, IL-10, IL-1RA). Kaplan-Meier survival analysis demonstrated patients with
high-serum sCD40L (> 35,000 ng/ml) had a poorer prognosis than those with low-serum sCD40L (log-rank, p = 0.015).
Multivariate Cox regression analysis yielded a hazard ratio of 2.509 (95% CI, 1.038–6.067, p = 0.041) for mortality in the
high-serum sCD40L group.
Conclusions: Serum sCD40L is correlated with immunosuppression and angiogenesis in PDAC carcinogenesis/
progression, and is a promising diagnostic and prognostic biomarker for PDAC superior to CA19-9 and CEA.
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CD40 ligand (CD40L) was initially identified as a T-cell
receptor for ligation of the co-stimulatory molecule CD40,
and CD40-CD40L interaction was considered as a key
event for effective adaptive immune response [1,2]. Sub-
sequently, CD40L was identified on the surface of non-
immune cells including activated platelets, endothelial
cells, and epithelial cells [3-5]. Activated T-lymphocytes
and platelets can release soluble CD40L (sCD40L) into
circulation [3], and both membrane-bound CD40L and
sCD40L can interact with CD40 which is expressed on
vascular cells and activated platelets, resulting in pro-
moting inflammatory and prothrombotic responses [3-6].
Additional studies reported that CD40-CD40L interaction
produces many angiogenesis-associated factors, such as
vascular endothelial growth factor (VEGF) [7-9]. Like this,
early studies mainly focused on the pathophysiological
role of CD40L in cardiovascular and immuno-inflamma-
tory diseases [9,10]. However, subsequent other studies
found that CD40-CD40L interaction affected tumor cell
migration, and then the role of soluble CD40L (sCD40L)
has gained interest in cancer [11]. Generally, tumor pro-
coagulant activities cause thrombin generation, which
induces platelet activation [12,13] and resultant release of
angiogenesis-associated cytokines [14]. In cancer patients,
sCD40L is more likely derived from activated platelets
than from T-cells [15]; therefore, sCD40L can affect can-
cer development and progression by inducing thrombotic
reactions and releasing angiogenesis-associated cytokines.
This idea is supported by evidence that cancer patients,
including those with pancreatic ductal adenocarcinoma
(PDAC), have significant platelet activation [16-18]. Wide-
spread expression of CD40 in human carcinomas also
supports the role of this ligand in cancer pathogenesis
[19]. Actually, several recent human studies have showed
the elevation of serum sCD40L levels in patients with
certain solid tumors and myeloproliferative neoplasms
[6,20-22]. But its exact role remains elusive yet.
PDAC is one of the most difficult malignancies to diag-
nose and treat. More than 80% of PDAC are surgically
unresectable at diagnosis because of the characteristics of
this disease (e.g., rapid progression and proximity to major
vessels, etc.) and delayed diagnosis, which can be caused
by complex, expensive, and often invasive current conven-
tional diagnostic methods and non-specific vague symp-
toms of PDAC [23]. Thus, the discovery of useful serum
biomarkers for PDAC is clinically valuable.
Although no information is currently available on the
clinical significance of sCD40L in PDAC, previous study
reporting that CD40 activation in islets and ductal cells
due to oxidative stress/inflammation produces various
cytokines/chemokines [24] suggests the potential role of
sCD40L in PDAC pathogenesis. Further, past studies
support the implication of sCD40L in PDAC pathogenesisby exhibiting the cancer-related coagulopathy (Trousseau’s
syndrome) in PDAC [18], and by showing the effect of
anti-platelet therapy to control PDAC metastasis in nude
mice [25].
In current study, we first evaluate the clinical significance
of sCD40L in PDAC patients compared with normal
healthy controls and patients with chronic pancreatitis (CP,
high-risk), and validate serum sCD40L as a potential
biomarker for PDAC compared with pre-existing PDAC
biomarkers, carbohydrate antigen 19–9 (CA19-9) and car-
cinoembryonic antigen (CEA) using prospectively collected
human serum samples.
Methods
Study subjects and sample collection
This study enrolled 190 subjects from the Yonsei Univer-
sity Health System: 75 subjects for initial biomarker iden-
tification (training dataset) and following 115 subjects
for independent validation. The study datasets included
3 groups according to the PDAC carcinogenic sequence:
normal, CP (high-risk), and PDAC.
For the initial training dataset, the sample size was
calculated to be 25 subjects per group using Russ Lenth’s
interactive power/sample size online calculator because
of the lack of information on the mean values for each
group. This sample size achieved a statistical power >
80%, assuming that there were 3 comparison groups, the
estimated standard deviation (SD) was 1, and the con-
fidence level was 0.05 (one-way analysis of variance
[ANOVA]). The independent validation dataset included
30 normal, 30 CP, and 55 PDAC patients. This sample
size allowed achievement of statistical power > 90% using
the Number Cruncher Statistical System Power Analysis
and Sample Size (NCSS PASS) program with the results
for mean and SD taken from the training dataset
(one-way ANOVA).
As normal controls, we enrolled age- and gender-
matched healthy individuals who underwent a medical
checkup, and were revealed to have normal pancreas on
imaging studies, and had no PDAC risk factors. CP
group included patients with typical radiological and/or
histopathological findings of CP. All PDAC patients were
diagnosed histopathologically using biopsy or surgical
specimens. Patients with acute or chronic illnesses such
as cardiovascular and immuno-inflammatory diseases were
excluded. Those with other cancers and/or other pan-
creatic malignancies besides ductal adenocarcinoma were
also excluded.
TNM classification of PDAC was determined according
to the American Joint Committee on Cancer (AJCC)
Staging Manual, 6th edition. A pathologist at the Yonsei
University Health System reviewed all histopathological
information. Blood samples were collected before treat-
ment initiation. Blood samples were stored at −80°C as
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Board of the Yonsei University Health System approved
this research, and all participants provided written in-
formed consent.
Measurement of serum cytokine levels using a
chemiluminescent immunoassay
Using a commercially available MILLIPLEX MAP Human
Cytokine/Chemokine Kit (Millipore, Billerica, MA, USA),
we measured the serum sCD40L levels. We also measured
the serum levels of angiogenesis-associated cytokines in-
cluding epidermal growth factor (EGF), VEGF, and inter-
leukin (IL)-8 and anti-inflammatory immunosuppressive
cytokines including IL-6, IL-10, and IL-1 receptor antag-
onist (IL-1RA). This kit allowed simultaneous quantifi-
cation of all tested cytokines. Briefly, the filter plate was
pre-wetted with 200 μL assay buffer for 10 min at room
temperature (RT), followed by vacuum removal of the
assay buffer. Twenty-five microliters of standard or con-
trol was added to the appropriate well, and 25 μL assay
buffer was added to the sample wells, but not the back-
ground well. Next, 25 μL of the appropriate matrix solu-
tion was added to the background, standard, and control
wells, followed by addition of 25 μL sample to appropriate
wells. After mixing, 25 μL beads were added, and the plate
was incubated overnight at 4°C with shaking. After incu-
bation, the fluid was removed and the plate was washed
twice. Detection antibodies (25 μL) were added, and
the plate was incubated for 1 h at RT with shaking.
Streptavidin-phycoerythrin (25 μL) was added to each
well containing 25 μL detection antibodies and was incu-
bated for 1 h at RT with shaking. The fluid was then
removed, the plate was washed, and 150 μL sheath fluid
was added. After re-suspension for 5 min, the median
fluorescent intensity was read on a Luminex 100™ IS and
analyzed using the logistic curve-fitting method to deter-
mine cytokine concentrations.
Measurement of serum levels of CA19-9 and CEA
Serum CA 19–9 and CEA levels were measured using
quality-controlled Vitros-3600 automatic analyzer (Ortho
Clinical Diagnostic, New York, USA) and Beckman
Access CEA assay (Beckman Coulter Inc. Chaska, USA),
respectively.
Statistical analysis
All assays were performed in duplicate in a blinded fash-
ion on the same day. Each value is expressed as the mean
with 25–75% standard deviation (SD). We used an inde-
pendent validation dataset to determine the reproducibil-
ity of the diagnostic potential of serum sCD40L for PDAC
that was determined using the training dataset. One-way
ANOVA test with multiple comparisons using the post-
hoc Bonferroni method was applied to compare meanserum levels of values among three groups. Receiver oper-
ator characteristic (ROC) curves were generated and the
area under the curve (AUC) was calculated to compare
the diagnostic accuracy of tested markers for predicting
PDAC. To validate the diagnostic potential of serum
sCD40L, CA19-9, CEA, and combinations of these 3
markers, we performed logistic regression analysis. Each
marker was included as a linear term. For comparisons
among each panel, the cut-off point ensured a target
sensitivity of around 80%. Spearman’s correlation (coeffi-
cient, γs) and Pearson’s correlation (coefficient, γp) analysis
were performed to assess the correlations between serum
values and non-continuous and continuous variables,
respectively.
Overall survival was estimated using the Kaplan-Meier
method, and the log-rank test was used to compare
patients with low-serum sCD40L levels (≤35,000 ng/mL)
and those with high-serum sCD40L levels (>35,000 ng/mL)
in the validation dataset. Univariate and multivariate Cox
proportional-hazards regression models were used to eva-
luate the prognostic potential of serum sCD40L in the
validation dataset.
A gastroenterologist and an MD of laboratory medi-
cine analyzed the data, with support from a statistician
who specializes in biomarker studies. P-values less than
0.05 (p < 0.05) were considered statistically significant.
Statistical analyses were performed using IBM SPSS
Statistics 20.0 (SPSS Inc, Chicago).
Results
Serum sCD40L levels along the PDAC carcinogenic
sequence in training set: comparison with serum CA19-9
and CEA
Serum sCD40L levels were significantly higher in the
PDAC group (30044.2 ± 9747.9 ng/mL) than in the CP
(17648.9 ± 7264.0 ng/mL) and normal control (9170.5 ±
5449.8 ng/mL) groups in the initial training dataset
(one-way ANOVA, p < 0.001; Table 1). Serum sCD40L
levels were also higher in the CP group than in the
normal group (post-hoc Bonferroni, p < 0.001). Similarly,
serum CA19-9 levels tended to increase along the PDAC
carcinogenic process (p < 0.001; Table 1). However, serum
CEA levels were not significantly different among three
groups (p = 0.428; Table 1).
Diagnostic accuracy of sCD40L for PDAC prediction in
training set
To compare the diagnostic accuracy of serum sCD40L
for PDAC compared with serum CA19-9 and CEA in
the training dataset, ROC curves were generated and
AUC was calculated (Figure 1a). Serum sCD40L exhib-
ited superior diagnostic potential for PDAC compared
with serum CA19-9 and CEA in the training dataset
(Figure 1a).
Table 1 Serum levels of sCD40L, CA19-9, and CEA in both training and independent validation datasets
(Training set) Groups (n)
Values Normal (n = 25) CP† (n = 25) PDAC (n = 25) p-value‡
Serum sCD40L (ng/ml) 9170.5 ± 5449.8* 17648.9 ± 7264.0 30044.2 ± 9747.9 < 0.001
Serum CA19-9 (U/ml) 7.9 ± 7.1 136.8 ± 329.8 5795.4 ± 7842.7 < 0.001
Serum CEA (ng/ml) 2.3 ± 1.5 2.9 ± 2.0 367.9 ± 1709.4 0.428
(Validation set) Groups (n)
Values Normal (n = 30) CP (n = 30) PDAC (n = 55) p-value‡
Serum sCD40L (ng/ml) 10540.1 ± 5159.9 18709.4 ± 8786.6 27924.6 ± 10202.9 < 0.001
Serum CA19-9 (U/ml) 8.5 ± 7.5 119.6 ± 299.7 3932.7 ± 6839.2 < 0.001
Serum CEA (ng/ml) 2.2 ± 1.4 2.6 ± 2.0 271.4 ± 1246.8 0.359
sCD40L, soluble CD40 ligand; CA19-9, carbohydrate antigen 19–9; CEA, carcinoembryonic antigen; CP, chronic pancreatitis; PDAC, pancreatic
ductal adenocarcinoma.
*All tested values are expressed as the mean ± standard deviation.
†We included CP patients as the high-risk group of PDAC.
‡One-way ANOVA test with the multiple comparisons using the post-hoc Bonferroni method is applied to compare the differences in the means among three
disease groups.
p < 0.05 (two-tailed) was considered to be statistically significant.
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sequence in independent validation dataset
Next, we tested whether our results from the training
dataset were reproducible by evaluating the diagnostic
potential of serum sCD40L for PDAC in an independent
validation dataset. The characteristics of patients in val-
idation dataset were shown in supplementary Additional
file 1. Consistent with the results of training dataset, serum
sCD40L levels in the validation dataset were significantly
higher in the PDAC group (27924.6 ± 10202.9 ng/mL)
than in the CP (18709.4 ± 8786.6 ng/mL) and normal
(10540.1 ± 5159.9 ng/mL) groups (p < 0.001; Table 1).
And serum sCD40L levels were also higher in the CP
group than in the normal group (p < 0.001).Figure 1 ROC curves of sCD40L, CA19-9, and CEA for PDAC screening
ROC curve.Diagnostic potential of sCD40L for predicting PDAC in the
validation dataset
ROC curve also exhibited the superior diagnostic potential
of serum sCD40L for predicting PDAC compared with
serum CA19-9 or CEA in the validation dataset (Figure 1b).
Logistic regression in the validation dataset demonstrated
that sCD40L had remarkable diagnostic potential for PDAC
screening, either alone or as part of a multiple-marker
panel (Table 2). When sCD40L was combined with
CA19-9, the specificity increased to 89.1% at 80% sensi-
tivity (cut-off point, 0.35; Table 2). When all of sCD40L,
CA19-9, and CEA were used in combination, the sensitiv-
ity and specificity in screening for PDAC were remarkably
increased (90.9% specificity at 84.4% sensitivity; Table 2).. (a) Training datasets. (b) Validation datasets. AUC, area under the
Table 2 Diagnostic accuracy of combinations of serum
sCD40L, CA19-9, and/or CEA to detect PDAC by logistic
regression in the validation dataset
Marker panel* Cut-off point† Sensitivity‡ Specificity
sCD40L 0.45 80.0% 85.5%
CA19-9 0.35 80.0% 72.7%
CEA 0.45 68.9% 60.0%
sCD40L + CA19-9 0.35 80.0% 89.1%
sCD40L + CEA 0.60 80.0% 85.5%
CA19-9 + CEA 0.41 80.0% 70.9%
sCD40L + CA19-9 + CEA 0.45 84.4% 90.9%
sCD40L, soluble CD40 ligand; CA19-9, carbohydrate antigen 19–9; CEA,
carcinoembryonic antigen; PDAC, pancreatic ductal adenocarcinoma.
*Each marker is included as a linear term and evaluated as a panel from one
to three markers combination.
†Cut-off point refers to the probability cut-off point to classify subjects as
having PDAC or non-PDAC in binary logistic regression.
‡For comparison among panels, the cut-off point ensures a target sensitivity of
around 80%.
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clinicopathological characteristics of PDAC
We analyzed the relationships between serum sCD40L
and clinicopathological characteristics of PDAC, com-
pared with CA19-9, in the validation dataset (Table 3).
Clinically, serum sCD40L was not affected by gender
(Spearman’s correlation; γs = −0.046, p = 0.740) or age
(γs = 0.076, p = 0.581). Pathologically, serum sCD40L was
not significantly correlated with T-stage (γs = 0.194,
p = 0.156), lymph node metastasis (γs = −0.146, p = 0.289),
or tumor size (γs = 0.035, p = 0.801). However, sCD40L was
significantly correlated with distant metastasis (γs = 0.294,
p = 0.030), overall stage (γs = 0.319, p = 0.017), and un-
resectability (γs = 0.342, p = 0.011) while CA19-9 wasTable 3 Relationships between serum sCD40L and
clinicopathological characteristics of PDAC, compared
with CA19-9 in the validation dataset
sCD40L CA19-9
γs (p-value) γs (p-value)
Gender (Male: Female) −0.046 (0.740) −0.213 (0.126)
Age (≤40, > 40 & ≤60, > 60) 0.076 (0.581) −0.181 (0.194)
T-stage (T1, T2, T3 ,T4) 0.194 (0.156) 0.095 (0.501)
Node metastasis (N0, N1) −0.146 (0.289) 0.362 (0.008)
Distant metastasis (M0, M1) 0.294(0.030) 0.425 (0.002)
Overall stage (I, II, III, IV) 0.319 (0.017) 0.431 (0.001)
Size (≤2 cm, > 2 cm & ≤5 cm, > 5 cm) 0.035 (0.801) 0.179 (0.201)
Unresectability* 0.342 (0.011) 0.269 (0.051)
sCD40L, soluble CD40 ligand; CA19-9, carbohydrate antigen 19–9; PDAC,
pancreatic ductal adenocarcinoma.
γs, Spearman’s correlation coefficient.
p < 0.05 (two-tailed) was considered to be statistically significant.
Statistically significant values are given in bold type.
*A tumor is defined as unresectable when a tumor invades celiac axis or
superior mesenteric artery (T4, N0-1, M0, stage III), or metastasizes to distant
sites (T1-4, N0-1, M1, stage IV).correlated with nodal metastasis (γs = 0.362, p = 0.008),
distant metastasis (γs = 0.425, p = 0.002), and overall stage
(γs = 0.431, p = 0.001).
Correlations between serum sCD40L and pro-angiogenic
or immunosuppressive cytokines in patients with PDAC in
the validation dataset
The results that serum sCD40L levels were correlated
with unresectability and distant metastasis of PDAC
indicate that sCD40L may be involved in PDAC pro-
gression as well as PDAC development. Previous report
showing the role of sCD40L in inducing the angiogenesis-
associated cytokines [14] also supports our hypothesis.
Based on the previous and our current results, we hypo-
thesized that sCD40L may affect the production of pro-
angiogenic cytokines during PDAC carcinogenesis, and
thereby contribute to promote the distant metastasis of
PDAC as well as PDAC development. As expect, serum
sCD40L was closely correlated with serum pro-angiogenic
cytokines, EGF (Pearson’s correlations; γp = 0.590, p < 0.001),
VEGF (γp = 0.389, p < 0.001), and IL-8 (γp = 0.195, p = 0.037;
Table 4) when the entire subjects of validation dataset
were evaluated. Serum sCD40L was also correlated with
serum EGF (γp = 0.397, p = 0.003) and VEGF (γp = 0.305,
p = 0.026), and it tended to be correlated with serum IL-8
(γp = 0.257, p = 0.058) when only PDAC patients were
evaluated.
Previous studies also suggested that elevated serum
sCD40L levels play an immunosuppressive role in cancer
patients [20]. Thus, we also evaluated correlations be-
tween serum sCD40L and serum anti-inflammatory
immunosuppressive cytokines (IL-6, IL-10, and IL-1RA).
When all cases were evaluated, serum sCD40L was posi-
tively correlated with serum IL-6 (γp = 0.203, p = 0.029),
IL-10 (γp = 0.215, p = 0.021), and IL-1RA (γp = 0.243,
p = 0.009; Table 4). For only PDAC patients, serum sCD40L
was not significantly correlated with IL-6 (γp = 0.209,
p = 0.126), IL-10 (γp = 0.224, p = 0.100), or IL-1RA
(γp = 0.248, p = 0.068). However, there was a tendency
toward positive correlations with serum sCD40L levels.
These results suggest that sCD40L affects PDAC deve-
lopment through induction of both immunosuppressive
cytokines (IL-6, IL-10, and IL-1RA) and pro-angiogenic
cytokines (EGF, VEGF, and IL-8), in agreement with pre-
vious studies [20,26]. And, sCD40L also may influence
on PDAC metastasis, mainly through induction of pro-
angiogenic cytokines (EGF, VEGF, and IL-8), and partially
immunosuppressive cytokines (IL-6, IL-10, and IL-1RA).
Diagnostic advantage of serum sCD40L to overcome the
limitations of CA19-9
Serum CA19-9 is the most widely used biomarker for
PDAC, but it sometimes does not correspond to a dis-
ease entity, making it difficult to differentiate between
Table 4 Relationships between serum sCD40L and pro-angiogenic or immunosuppressive cytokines in patients with
PDAC in the validation dataset
(All groups) EGF VEGF IL-8 IL-6 IL-10 IL-1RA
Serum sCD40L (γp) 0.590 0.389 0.195 0.203 0.215 0.243
(p-value) < 0.001 < 0.001 0.037 0.029 0.021 0.009
(PDAC group) EGF VEGF IL-8 IL-6 IL-10 IL-1RA
Serum sCD40L (γp) 0.397 0.305 0.257 0.209 0.224 0.248
(p-value) 0.003 0.026 0.058 0.126 0.100 0.068
Pro-angiogenic cytokines, EGF, VEGF, and IL-8; immunosuppressive cytokines, IL-6, IL-10, and IL-1RA.
γp, Pearson’s correlation coefficient.
p < 0.05 (two-tailed) was considered to be statistically significant.
Statistically significant values are given in bold type.
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whether serum sCD40L could differentiate PDAC from
benign conditions in cases where the levels of CA19-9
are inappropriately high in normal subjects or inappro-
priately low in patients with PDAC in the validation
dataset. First, we compared the serum levels of sCD40L
and CA19-9 between the cancer and non-cancer groups
in subjects with low-serum CA19-9 levels (≤40 ng/mL)
and those with high-serum CA19-9 levels (>40 ng/mL).
Serum sCD40L levels were definitively different between
the cancer and non-cancer groups in both low-CA19-9
and high-CA19-9 groups independent of serum CA19-9
levels (each p < 0.001; data not shown); this means that
serum sCD40L can differentiate between PDAC and non-
cancer in cases where serum CA19-9 levels were not
significantly different between cancer and non-cancer
groups. Logistic regression showed that serum sCD40L
exhibited remarkable diagnostic potential to differentiate
between PDAC and non-cancer conditions in both the
low and high CA19-9 level groups (Table 5).
Prediction of PDAC prognosis by serum sCD40L levels
Fifty-two PDAC patients in the validation dataset were in-
cluded in the final survival analysis. Three of the original
55 patients were excluded due to follow-up loss. The
maximum follow-up time was 1,576 days, and the median
follow-up time was 282 days. Kaplan-Meier survival
curves showed that PDAC patients with high-levels of
serum sCD40L (>35,000 ng/mL) had a significantly worse
prognosis than those with low-levels (≤35,000 ng/mL,Table 5 Diagnostic advantages of serum sCD40L for different
of CA19-9 are inappropriate*
Low-serum CA 19–9 subjects
Cut-off value Sensitivity Spec
sCD40L (ng/ml) 20000 80.0% 86.7%
Sensitivity and specificity of serum sCD40L to differentiate PDAC from non-cancer i
levels when serum CA19-9 does not correspond to a disease entity.
sCD40L, soluble CD40 ligand; CA19-9, carbohydrate antigen 19–9; CEA, carcinoemb
* This means that the cases when CA19-9 are inappropriately high in normal subjeclog-rank, p = 0.015; Figure 2). The median survival was
190 days (95% confidence interval [CI], 160.9–219.1 days)
in patients with high-levels of serum sCD40L versus
432 days (95% CI, 205.5-658.5) in patients with low-levels.
Univariate Cox proportional-hazards regression model
showed that distant metastasis, unresectability, large
tumor size, low Karnofsky performance status scale, high-
serum CEA (>3 ng/mL) levels, and high-serum sCD40L
(>35,000 ng/mL) levels were statistically significant poor
prognostic factors for PDAC (Table 6). The hazard ratio
(HR) of high-serum sCD40L levels for mortality was 2.468
(95% CI, 1.162–5.242; p = 0.019).
Multivariate Cox proportional-hazards regression model
demonstrated that distant metastasis, large tumor Size,
low Karnofsky performance status scale, and high-serum
sCD40L remained as significant poor prognostic factors
from the univariate analysis after adjustment (Table 6).
The adjusted HR for high-serum sCD40L levels was 2.509
(95% CI, 1.038-6.067; p = 0.041).
Discussion
This study evaluated the role of sCD40L in PDAC
patients using prospectively collected human serum
samples. To our knowledge, this study is the first report
to validate serum sCD40L as a potential diagnostic and
prognostic biomarker for PDAC. We also provide the
possible clinical evidence that elevated serum sCD40L
levels is linked to PDAC development and metastasis
through neoangiogenesis and immunosuppression. We
validated the predictive potentials of serum sCD40L foriation of PDAC from non-cancer in cases where the levels
High-serum CA 19–9 subjects
ificity Cut-off value Sensitivity Specificity
20000 77.0% 85.0%
n subjects with low-serum (≤40 ng/mL) or high-serum CA19-9 (>40 ng/mL)
ryonic antigen; PDAC, pancreatic ductal adenocarcinoma.
ts or inappropriately low in patients with PDAC in the validation dataset.
Figure 2 Kaplan-Meier survival curves for PDAC patients with high-serum (>35,000 ng/ml) vs. low-serum (≤35,000 ng/mL) sCD40L levels.
Log-rank test, p = 0.015. SD, standard deviation; CI, confidence interval.
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ducibility in an independent dataset. We also followed
the Standards for Reporting of Diagnostic Accuracy
(STARD) statement [27] and the Reporting recommen-
dations for tumor marker prognostic studies (REMARK)
guideline [28].Table 6 Univariate and adjusted-multivariate Cox proportion
validation dataset
Univariate analysis
Gender (male vs. female)
Age (≤40, > 40 & ≤60, > 60)
T-stage (T1, T2, T3 ,T4)
Node metastasis (N0, N1)
Distant metastasis (M0, M1)
Unresectability (resectable vs. unresectable)
Tumor Size (≤2 cm, > 2 cm & ≤ 5 cm, > 5 cm)
Histological differentiation (Well, Moderate, Poor; n)
Karnofsky performance status scale (continuous variable)*
High-serum CA19-9 (≤40 U/ml vs. > 40 U/ml)
High-serum CEA (≤3 ng/ml vs. > 3 ng/ml)
High-serum sCD40L (≤35,000 ng/ml vs. > 35,000 ng/ml)
Multivariate analysis
Distant metastasis (M0, M1)
Unresectability (resectable vs. unresectable)
Tumor Size (≤2 cm, > 2 cm & ≤ 5 cm, > 5 cm)
Karnofsky performance status scale (continuous variable)*
High-serum CEA (≤3 ng/ml vs. > 3 ng/ml)
High-serum sCD40L (≤35,000 ng/ml vs. > 35,000 ng/ml)
HR, hazard ratio of mortality; CI, confidence interval; sCD40L, soluble CD40 ligand; C
p-value of < 0.05 is considered to be statistically significant.
*This scale was evaluated at diagnosis before treatment start.
†Hazard ratios (HRs) were adjusted for other variables by the “enter” method in muSerum sCD40L levels were significantly elevated in
PDAC patients compared with age- and gender-matched
non-cancer subjects in training and validation datasets,
which result indicates serum sCD40L as a promising
biomarker candidate for PDAC. ROC curve and esti-
mated sensitivity and specificity by logistic regressional-hazards estimates for patients with PDAC in the
HRs 95% CI p-value
0.583 0.280-1.211 0.148
0.649 0.359-1.175 0.154
1.428 0.902-2.261 0.129
1.960 0.810-4.745 0.136
3.558 1.695-7.469 0.001
2.917 1.025-8.298 0.045
2.419 1.191-4.917 0.015
1.154 0.777-1.714 0.478
0.962 0.936-0.988 0.005
1.811 0.788-4.160 0.162
2.137 1.062-4.298 0.033
2.468 1.162-5.242 0.019
HRs† 95% CI p-value
3.469 1.375-8.749 0.008
0.588 0.168-2.060 0.406
2.454 1.075-5.602 0.033
0.969 0.940-0.998 0.038
1.354 0.549-3.340 0.511
2.509 1.038-6.067 0.041
A19-9, cancer antigen 19–9; CEA, carcinoembryonic antigen.
ltivariate Cox analysis.
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http://www.translational-medicine.com/content/12/1/102support our hypothesis (Figure 1 and Table 2). Serum
sCD40L showed stronger PDAC prediction power than
CA19-9 and CEA. Nevertheless, the use of serum sCD40L
as a single biomarker for PDAC may be limited because
serum sCD40L can be elevated in other cancers [20-22]
and certain benign disorders including cardiovascular
diseases or immuno-inflammatory diseases [9,10]. There-
fore, combining sCD40L with pre-existing biomarkers for
PDAC, such as CA19-9 and/or CEA would overcome this
limitation by increasing specificity for PDAC. As expected,
combination of serum sCD40L with CA19-9 increased the
specificity nearly 90% at a sensitivity of 80%. Combining
all of sCD40L, CA19-9, and CEA produced the highest
sensitivity and specificity (90.9% specificity at 84.4% sen-
sitivity; Table 2), confirming that serum sCD40L is a
valuable diagnostic biomarker as both alone and part of
multiple-marker panels. Additionally, serum sCD40L was
able to overcome the limitations of CA19-9 in patients
where CA19-9 did not correspond to a disease entity, such
as in the cases of benign biliary obstruction or combined
benign liver diseases. Serum sCD40L also aids differen-
tiation between resectable and unresectable cases, and
negative and positive distant metastasis. Therefore, serum
sCD40L can provide insight into whether PDAC is curable
and help avoid unnecessary surgical procedures.
Kaplan-Meier survival analysis and Cox proportional-
hazards regression models indicated that PDAC patients
with high-serum sCD40L (>35,000 ng/mL) levels had
poorer prognosis than those with low-serum sCD40L
(≤35,000 ng/mL) levels in agreement with previous re-
ports [29].
Many past studies have tried to explain the pathogen-
esis of sCD40L-related carcinogenesis and progression.
Although early studies addressed the pro-apoptotic cap-
acity of the CD40-CD40L pair [30], subsequent studies
suggested that sCD40L may induce an anti-apoptotic
signal under certain stimuli [31]. Several studies have
also suggested that cancer-mediated thrombin generation
by interaction between tumor cell CD40 and platelet-
derived sCD40L is involved in tumor cell growth, motility,
and angiogenesis through activation of gene transcription
that promotes tumor metastasis and angiogenesis [32,33].
In tumor-prone transgenic mice, CD40-mediated neovas-
cularization was essential for early-stage tumorigenesis
[34]. Recently, serum sCD40L was found to negatively
regulate cancer immune responses [20].
Like previous studies, we observed that serum sCD40L
levels correlated with several well-known pro-angiogenic
cytokines including EGF, VEGF, and IL-8 when either all
subjects or only PDAC patients were evaluated. On the
other hand, immunosuppressive cytokines including
IL-6, IL-10, and IL-1RA exhibited strong positive corre-
lations with sCD40L when all subjects were evaluated,
although there were weak positive correlations when onlyPDAC patients were analyzed. These results imply that
sCD40L may induce the pro-angiogenic cytokines pro-
duction, which can affect both PDAC development and
metastasis like previous studies [32-34]. Also, circulating
sCD40L may enhance immunosuppressive cytokines pro-
duction, which can affect mainly PDAC development
disturbing tumor immune surveillance. To confirm the
causal relationship between serum sCD40L and these
cytokines during PDAC development and progression,
well-designed cell biological analysis and animal experi-
ments are further needed.
Although the sample sizes achieved > 80% statistical
power in all tested datasets, and we also validated our
findings of initial training dataset in independent validation
datasets, the sample sizes of present study is relatively
small because of the difficulty of pathological confirmation
of PDAC and resultant limitation of patient enrollment.
Therefore, further large-scale studies should follow to
confirm our current results.Conclusion
We demonstrated the clinical significance of sCD40L
in PDAC development and progression using prospect-
ively collected human serum samples, and we validated
serum sCD40L as a useful serum biomarker for PDAC by
demonstrating its predictive and prognostic potentials and
its ability to overcome the limitations of serum CA19-9.
We hope that current study can help the early diagnosis
of PDAC and improvement of prognosis of PDAC.Additional file
Additional file 1: Clinicopathological features of subjects in the
validation dataset.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HWC and JBL contributed the conception and design of the study. HWC
and JBL collected and stored all the samples. JBL acquired the
quantitative data of serum sCD40L and cytokines concentration. HWC
conducted statistical analysis of all data. JBL supervised all experiments.
HWC and JBL drafted the manuscript. Both authors have given final
approval of the version to be published and have agreed to be
accountable for all aspects of the work.
Acknowledgements
This work was supported by a faculty research grant from the Yonsei
University College of Medicine for 2009 (6-2009-0091).
Author details
1Department of Internal Medicine, Division of Gastroenterology, International
ST. Mary’s Hospital, Incheon, Republic of Korea. 2Department of Laboratory
Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Received: 20 February 2014 Accepted: 8 April 2014
Published: 21 April 2014
Chung and Lim Journal of Translational Medicine 2014, 12:102 Page 9 of 9
http://www.translational-medicine.com/content/12/1/102References
1. van Kooten C, Banchereau J: CD40-CD40 ligand. J Leukoc Biol 2000, 67:2–17.
2. Noelle RJ: CD40 and its ligand in host defense. Immunity 1996, 4:415–419.
3. Aukrust P, Müller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO,
Forfang K, Frøland SS, Gullestad L: Enhanced levels of soluble and
membrane-bound CD40 ligand in patients with unstable angina.
Possible reflection of T lymphocyte and platelet involvement in the
pathogenesis of acute coronary syndromes. Circ 1999, 100:614–620.
4. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ: Molecular
mechanism and function of CD40/CD40L engagement in the immune
system. Immunol Rev 2009, 229:152–172.
5. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus
G, Kroczek RA: CD40 ligand on activated platelets triggers an
inflammatory reaction of endothelial cells. Nature 1998, 391:591–594.
6. Roselli M, Mineo TC, Basili S, Martini F, Mariotti S, Aloe S, Del Monte G,
Ambrogi V, Spila A, Palmirotta R, D’Alessandro R, Davì G, Guadagni F,
Ferroni P: Soluble CD40 ligand plasma levels in lung cancer. Clin Cancer
Res 2004, 10:610–614.
7. Dormond O, Contreras AG, Meijer E, Datta D, Flynn E, Pal S, Briscoe DM:
CD40-induced signaling in human endothelial cells results in
mTORC2- and Akt-dependent expression of vascular endothelial growth
factor in vitro and in vivo. J Immunol 2008, 181:8088–8095.
8. Melter M, Reinders ME, Sho M, Pal S, Geehan C, Denton MD, Mukhopadhyay
D, Briscoe DM: Ligation of CD40 induces the expression of vascular
endothelial growth factor by endothelial cells and monocytes and
promotes angiogenesis in vivo. Blood 2000, 96:3801–3808.
9. Danese S, Scaldaferri F, Vetrano S, Stefanelli T, Graziani C, Repici A, Ricci R,
Straface G, Sgambato A, Malesci A, Fiocchi C, Rutella S: Critical role of the
CD40 CD40-ligand pathway in regulating mucosal inflammation-driven
angiogenesis in inflammatory bowel disease. Gut 2007, 56:1248–1256.
10. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM: Soluble CD40L and
cardiovascular risk in women. Circ 2001, 104:2266–2268.
11. Tai YT, Podar K, Mitsiades N, Lin B, Mitsiades C, Gupta D, Akiyama M, Catley
L, Hideshima T, Munshi NC, Treon SP, Anderson KC: CD40 induces human
multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/
NF-kappa B signaling. Blood 2003, 101:2762–2769.
12. Cavanaugh PG, Sloane BF, Honn KV: Role of the coagulation system in
tumor cell-induced platelet aggregation and metastasis. Haemostasis
1988, 18:37–46.
13. Biggerstaff JP, Seth N, Amirkhosravi A, Amaya M, Fogarty S, Meyer TV,
Siddiqui F, Francis JL: Soluble fibrin augments platelet/tumor cell
adherence in vitro and in vivo, and enhances experimental metastasis.
Clin Exp Metastasis 1999, 17:723–730.
14. Roselli M, Mineo TC, Basili S, Mariotti S, Martini F, Bellotti A, Ambrogi V,
Spila A, D’Alessandro R, Gazzaniga PP, Guadagni F, Ferroni P: Vascular
endothelial growth factor (VEGF-A) plasma levels in non-small cell lung
cancer: relationship with coagulation and platelet activation markers.
Thromb Haemostasis 2003, 89:177–184.
15. Freedman JE: CD40-CD40L and platelet function: beyond hemostasis.
Circ Res 2003, 92:944–946.
16. Osada J, Rusak M, Kamocki Z, Dabrowska MI, Kedra B: Platelet activation in
patients with advanced gastric cancer. Neoplasma 2010, 57:145–150.
17. Dammacco F, Vacca A, Procaccio P, Ria R, Marech I, Racanelli V: Cancer-
related coagulopathy (Trousseau’s syndrome): review of the literature
and experience of a single center of internal medicine. Clin Exp Med
2013, 13:85–97.
18. Pinzon R, Drewinko B, Trujillo JM, Guinee V, Giacco G: Pancreatic carcinoma
and Trousseau’s syndrome: experience at a large cancer center. J Clin
Oncol 1986, 4:509–514.
19. Sabel MS, Yamada M, Kawaguchi Y, Chen FA, Takita H, Bankert RB: CD40
expression on human lung cancer correlates with metastatic spread.
Canc Immunol Immunother 2000, 49:101–108.
20. Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, Madan RA, Gulley
JL, Schlom J: Elevated serum soluble CD40 ligand in cancer patients may
play an immunosuppressive role. Blood 2012, 120:3030–3038.
21. Younes A, Snell V, Consoli U, Clodi K, Zhao S, Palmer JL, Thomas EK,
Armitage RJ, Andreeff M: Elevated levels of biologically active soluble
CD40 ligand in the serum of patients with chronic lymphocytic
leukaemia. Br J Haematol 1998, 100:135–141.
22. Caggiari L, Guidoboni M, Vaccher E, Barzan L, Franchin G, Gloghini A,
Martorelli D, Zancai P, Bortolin MT, Mazzucato M, Serraino D, Carbone A, DePaoli P, Dolcetti R: High serum levels of soluble CD40-L in patients with
undifferentiated nasopharyngeal carcinoma: pathogenic and clinical
relevance. Infect Agent Canc 2007, 2:5–15.
23. Li D, Xie K, Wolff R, Abbruzzese J: Pancreatic cancer. Lancet 2004,
363:1049–1057.
24. Klein D, Timoneri F, Ichii H, Ricordi C, Pastori RL: CD40 activation in human
pancreatic islets and ductal cells. Diabetologia 2008, 51:1853–1861.
25. Tzanakakis GN, Agarwal KC, Vezeridis MP: Prevention of human pancreatic
cancer cell-induced hepatic metastasis in nude mice by dipyridamole
and its analog RA-233. Canc 1993, 71:2466–2471.
26. Bergmann S, Pandolfi PP: Giving blood: a new role for CD40 in
tumorigenesis. J Exp Med 2006, 203:2409–2412.
27. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM,
Lijmer JG, Moher D, Rennie D, de Vet HC: Standards for reporting of
diagnostic accuracy: towards complete and accurate reporting of studies
of diagnostic accuracy: the STARD initiative. Standards for reporting of
diagnostic accuracy. Clin Chem 2003, 49:1–6.
28. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM:
Reporting recommendations for tumor marker prognostic studies.
J Clin Oncol 2005, 23:9067–9072.
29. Hock BD, McKenzie JL, Patton NW, Drayson M, Taylor K, Wakeman C,
Kantarjian H, Giles F, Albitar M: Circulating levels and clinical significance
of soluble CD40 in patients with hematologic malignancies. Canc 2006,
106:2148–2157.
30. Tong AW, Papayoti MH, Netto G, Armstrong DT, Ordonez G, Lawson JM,
Stone MJ: Growth-inhibitory effects of CD40 ligand (CD154) and its
endogenous expression in human breast cancer. Clin Canc Res 2001,
7:691–703.
31. Yamaguchi H, Tanaka F, Sadanaga N, Ohta M, Inoue H, Mori M: Stimulation
of CD40 inhibits Fas- or chemotherapy-mediated apoptosis and
increases cell motility in human gastric carcinoma cells. Int J Oncol 2003,
23:1697–1702.
32. Amirkhosravi A, Amaya M, Desai H, Francis JL: Platelet-CD40 ligand
interaction with melanoma cell and monocyte CD40 enhances cellular
procoagulant activity. Blood Coagul Fibrinolysis 2002, 13:505–512.
33. Tai YT, Podar K, Gupta D, Lin B, Young G, Akiyama M, Anderson KC: CD40
activation induces p53-dependent vascular endothelial growth factor
secretion in human multiple myeloma cells. Blood 2002, 99:1419–1427.
34. Chiodoni C, Iezzi M, Guiducci C, Sangaletti S, Alessandrini I, Ratti C, Tiboni F,
Musiani P, Granger DN, Colombo MP: Triggering CD40 on endothelial cells
contributes to tumor growth. J Exp Med 2006, 203:2441–2450.
doi:10.1186/1479-5876-12-102
Cite this article as: Chung and Lim: Clinical significance of elevated
serum soluble CD40 ligand levels as a diagnostic and prognostic tumor
marker for pancreatic ductal adenocarcinoma. Journal of Translational
Medicine 2014 12:102.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
